Methylprednisolone (MP)

DRUG4 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Zhangjiagang First People's Hospital, Konya City Hospital, University of Belgrade

Conditions

Bone Marrow FailureDyskeratosis CongenitaFanconi AnemiaMACEMortalityMyelodysplastic SyndromesMyocardial InjuryNeuromuscular Block, Residual

Phase 2

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

RecruitingNCT03579875

Masonic Cancer Center, University of MinnesotaBone Marrow Failure, Dyskeratosis Congenita, Fanconi Anemia +5

Start: 2018-11-13End: 2029-01-05Target: 48Updated: 2026-01-30

Phase 4

Methylprednisolone for Moderate to Severe Traumatic Brain Injury

Not yet recruitingNCT07180277

Zhangjiagang First People's HospitalTraumatic Brain Injury

Start: 2025-10-01End: 2028-03-01Target: 520Updated: 2025-09-18

Unknown Phase

Methylprednisolone vs Dexamethasone: Effects on Sugammadex Reversal, Pain, and Nausea in Adults

Not yet recruitingNCT07187037

Konya City HospitalNeuromuscular Block, Residual, Pain, Postoperative Nausea

Start: 2025-10-01End: 2026-04-30Target: 130Updated: 2025-09-22

Steroid Treatment to Prevent Thoracic Endovascular Aortic Repair Postimplantation Syndrome

Not yet recruitingNCT07328906

University of BelgradeMACE, Mortality, Myocardial Injury +1

Start: 2026-01-31End: 2029-01-31Target: 174Updated: 2026-01-12

Related Papers

TCRα/β Depleted Mobilized Pbscs without Calcineurin Inhibitors in Patients with Fanconi Anemia

Blood2024-11-05